Editas Medicine, Inc. (EDIT)
1.68
-0.09
(-5.08%)
USD |
NASDAQ |
Feb 12, 16:00
1.67
-0.01
(-0.60%)
Pre-Market: 09:28
Editas Medicine Cash from Investing (Quarterly) : 39.57M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| ADMA Biologics, Inc. | -14.37M |
| Arcutis Biotherapeutics, Inc. | -25.25M |
| Biogen, Inc. | -1.232B |
| Cogent Biosciences, Inc. | -155.05M |
| ACADIA Pharmaceuticals, Inc. | -79.35M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -30.84M |
| Cash from Financing (Quarterly) | 17.17M |
| Free Cash Flow | -180.70M |
| Free Cash Flow Per Share (Quarterly) | -0.3472 |
| Free Cash Flow to Equity (Quarterly) | -32.19M |
| Free Cash Flow to Firm (Quarterly) | -28.88M |
| Free Cash Flow Yield | -126.5% |